Subsidy Information and Financing Scheme MAFTafamidis Capsule 61 mg Additional clinical criteria applies Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
Drug Guidance for Subsidy 04/06/2024 Tafamidis for treating transthyretin amyloid cardiomyopathy The Ministry of Health’s Drug Advisory Committee has recommended: Tafamidis 61 mg capsule for... See all × 04/06/2024 Tafamidis for treating transthyretin amyloid cardiomyopathy The Ministry of Health’s Drug Advisory Committee has recommended: Tafamidis 61 mg capsule for treating transthyretin amyloid cardiomyopathy. Funding status RTafamidis 61 mg capsule is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024. RTafamidis should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with transthyretin amyloid cardiomyopathy. NRMAF assistance does not apply to any other formulations or strengths of tafamidis.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 61 mg National Heart Centre Tan Tock Seng Hospital
ORAL Select a brand starting with the letter: V VYNDAMAX SOFT GELATIN CAPSULE 61MG [SIN15894P] VYNDAQEL SOFT GELATIN CAPSULE 20MG [SIN15893P]